Anaplastic glioma: current treatment and management

被引：21

作者：

Le Rhun, Emilie ^{[1
,2
]}

Taillibert, Sophie ^{[3
]}

Chamberlain, Marc C. ^{[4
]}

机构：

[1] Univ Hosp, Roger Salengro Hosp, Dept Neurooncol, Lille, France

[2] Ctr Oscar Lambret, Neurol Unit, Dept Med Oncol, F-59020 Lille, France

[3] Univ Paris 06, Pitie Salpetriere Hosp, Mazarin & Radiat Oncol, Neurol Unit, Paris, France

[4] Univ Washington, Neurol & Neurol Surg, Fred Hutchinson Res Canc Ctr, Seattle, WA 98195 USA

来源：

EXPERT REVIEW OF NEUROTHERAPEUTICS | 2015年 / 15卷 / 06期

关键词：

1p/19q codeletion; anaplastic glioma; ATRX; bevacizumab; chemotherapy; IDH1; MGMT promoter methylation; molecular biomarkers; nitrosourea; radiotherapy; temozolomide; PHASE-II TRIAL; OLIGODENDROGLIAL BRAIN-TUMORS; BEVACIZUMAB PLUS IRINOTECAN; RECURRENT MALIGNANT GLIOMAS; ISOCITRATE DEHYDROGENASE 1; MOLECULAR-GENETIC ANALYSIS; MGMT PROMOTER METHYLATION; PROGRESSION-FREE SURVIVAL; HIGH-GRADE GLIOMAS; EUROPEAN-ORGANIZATION;

D O I：

10.1586/14737175.2015.1042455

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Anaplastic glioma (AG) is divided into three morphology-based groups (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma) as well as three molecular groups (glioma-CpG island methylation phenotype [G-CIMP] negative, G-CIMP positive non-1p19q codeleted tumors and G-CIMP positive codeleted tumors). The RTOG 9402 and EORTC 26951 trials established radiotherapy plus (procarbazine, lomustine, vincristine) chemotherapy as the standard of care in 1p/19q codeleted AG. Uni-or non-codeleted AG are currently best treated with radiotherapy only or alkylator-based chemotherapy only as determined by the NOA-04 trial. Maturation of NOA-04 and results of the currently accruing studies, CODEL (for codeleted AG) and CATNON (for uni or non-codeleted AG), will likely refine current up-front treatment recommendations for AG.

引用

页码：601 / 620

页数：20

共 146 条

[1] Survey of treatment recommendations for anaplastic oligodendroglioma [J].

Abrey, Lauren E. ;

Louis, David N. ;

Paleologos, Nina ;

Lassman, Andrew B. ;

Raizer, Jeffrey J. ;

Mason, Warren ;

Finlay, Jonathan ;

MacDonald, David R. ;

DeAngelis, Lisa M. ;

Cairncross, J. Gregory .

NEURO-ONCOLOGY, 2007, 9 (03) :314-318

[2] Medical therapy of gliomas [J].

Ahluwalia, Manmeet S. ;

Chang, Susan M. .

JOURNAL OF NEURO-ONCOLOGY, 2014, 119 (03) :503-512

[3] Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss [J].

Arita, Hideyuki ;

Narita, Yoshitaka ;

Fukushima, Shintaro ;

Tateishi, Kensuke ;

Matsushita, Yuko ;

Yoshida, Akihiko ;

Miyakita, Yasuji ;

Ohno, Makoto ;

Collins, V. Peter ;

Kawahara, Nobutaka ;

Shibui, Soichiro ;

Ichimura, Koichi .

ACTA NEUROPATHOLOGICA, 2013, 126 (02) :267-276

[4] IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection [J].

Beiko, Jason ;

Suki, Dima ;

Hess, Kenneth R. ;

Fox, Benjamin D. ;

Cheung, Vincent ;

Cabral, Matthew ;

Shonka, Nicole ;

Gilbert, Mark R. ;

Sawaya, Raymond ;

Prabhu, Sujit S. ;

Weinberg, Jeffrey ;

Lang, Frederick F. ;

Aldape, Kenneth D. ;

Sulman, Erik P. ;

Rao, Ganesh ;

McCutcheon, Ian E. ;

Cahill, Daniel P. .

NEURO-ONCOLOGY, 2014, 16 (01) :81-91

[5] Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma [J].

Bettegowda, Chetan ;

Agrawal, Nishant ;

Jiao, Yuchen ;

Sausen, Mark ;

Wood, Laura D. ;

Hruban, Ralph H. ;

Rodriguez, Fausto J. ;

Cahill, Daniel P. ;

McLendon, Roger ;

Riggins, Gregory ;

Velculescu, Victor E. ;

Oba-Shinjo, Sueli Mieko ;

Marie, Suely Kazue Nagahashi ;

Vogelstein, Bert ;

Bigner, Darell ;

Yan, Hai ;

Papadopoulos, Nickolas ;

Kinzler, Kenneth W. .

SCIENCE, 2011, 333 (6048) :1453-1455

[6] Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma [J].

Brada, Michael ;

Stenning, Sally ;

Gabe, Rhian ;

Thompson, Lindsay C. ;

Levy, David ;

Rampling, Roy ;

Erridge, Sara ;

Saran, Frank ;

Gattamaneni, Rao ;

Hopkins, Kirsten ;

Beall, Sarah ;

Collins, V. Peter ;

Lee, Siow-Ming .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4601-4608

[7] Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy - A phase II study [J].

Brandes, AA ;

Tosoni, A ;

Vastola, F ;

Pasetto, LM ;

Coria, B ;

Danieli, D ;

Luzzolino, P ;

Gardiman, M ;

Talacchi, A ;

Ermani, M .

CANCER, 2004, 101 (09) :2079-2085

[8] Temozolomide as a second-line systemic regimen in recurrent high-grade glioma:: A phase II study [J].

Brandes, AA ;

Ermani, M ;

Basso, U ;

Amistà, P ;

Berti, F ;

Scienza, R ;

Rotilio, A ;

Pinna, G ;

Gardiman, M ;

Monfardini, S .

ANNALS OF ONCOLOGY, 2001, 12 (02) :255-257

[9] Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study [J].

Brandes, Alba A. ;

Tosoni, Alicia ;

Cavallo, Giovanna ;

Reni, Michele ;

Franceschi, Enrico ;

Bonaldi, Laura ;

Bertorelle, Roberta ;

Gardiman, Marina ;

Ghimenton, Claudio ;

Iuzzolino, Paolo ;

Pession, Annalisa ;

Blatt, Valeria ;

Ermani, Mario .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4746-4753

[10] PLACEBO-CONTROLLED TRIAL OF SAFETY AND EFFICACY OF INTRAOPERATIVE CONTROLLED DELIVERY BY BIODEGRADABLE POLYMERS OF CHEMOTHERAPY FOR RECURRENT GLIOMAS [J].

BREM, H ;

PIANTADOSI, S ;

BURGER, PC ;

WALKER, M ;

SELKER, R ;

VICK, NA ;

BLACK, K ;

SISTI, M ;

BREM, S ;

MOHR, G ;

MULLER, P ;

MORAWETZ, R ;

SCHOLD, SC .

LANCET, 1995, 345 (8956) :1008-1012

← 1 2 3 4 5 6 7 8 9 10 →